Table 4.
Hazard ratios (95% confidence intervals) for development of 50% decline in eGFR or KRT (transplant or dialysis) among 255 children with glomerular disease contributing 808 person-years of follow-up and 90 composite events
| Serum Bicarbonate | Model 1 | Model 2 | Model 3 | Model 4 |
|---|---|---|---|---|
| Baseline bicarbonate | ||||
| >22 meq/L | 1 | 1 | 1 | 1 |
| 19–22 meq/L, HR (95% CI) | 1.79 (1.14 to 2.81)a | 1.28 (0.81 to 2.04) | 1.28 (0.80 to 2.05) | 1.28 (0.80 to 2.05) |
| ≤18 meq/L, HR (95% CI) | 1.94 (0.92 to 4.09) | NE | NE | NE |
| Time-varying bicarbonate | ||||
| >22 meq/L | 1 | 1 | 1 | 1 |
| 19–22 meq/L, HR (95% CI) | 2.83 (1.80 to 4.47)a | 2.17 (1.35 to 3.48)a | 1.86 (1.15 to 3.02)a | 1.74 (1.07 to 2.85)a |
| ≤18 meq/L, HR (95% CI) | 8.92 (4.84 to 16.45)a | 3.27 (1.65 to 6.49)a | 2.21 (1.08 to 4.56)a | 2.16 (1.05 to 4.44)a |
Model 1: unadjusted model. Model 2: model 1 plus adjustment for baseline age (centered at 10), male sex, white race, baseline eGFR (<30, 30–45, 45–60, or ≥60 ml/min per 1.73 m2), and proteinuria (<0.5, 0.5–2.0, or ≥2.0 mg/mg). Model 3: model 2 plus adjustment for anemia and phosphate (centered at 4.5 mg/dl). Model 4: model 3 plus adjustment for hypertension and alkali therapy use. Baseline models 2, 3, and 4 included 237 children with 82 composite events. HR, hazard ratio; 95% CI, 95% confidence interval; NE: not estimated in adjusted models due to small sample size (n=18, 8 events).
Indicates significance.